Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

FBIO

Fortress Biotech Inc

Dec 08 • 04:00PM ET

3.12

Dollar change -0.18
Percentage change -5.45	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-24.57	Insider Own	49.55%	Shs Outstand	14.83M	Perf Week	43.78%
Market Cap	46.27M	Forward P/E	-	EPS next Y	-3.18	Insider Trans	33.27%	Shs Float	7.48M	Perf Month	45.12%
Income	-82.32M	PEG	-	EPS next Q	-2.39	Inst Own	10.10%	Short Float / Ratio	3.47% / 0.56	Perf Quarter	-43.28%
Sales	80.97M	P/S	0.57	EPS this Y	22.34%	Inst Trans	-15.71%	Short Interest	0.26M	Perf Half Y	-64.47%
Book/sh	27.98	P/B	0.11	EPS next Y	71.86%	ROA	-33.03%	Target Price	12.50	Perf Year	-68.48%
Cash/sh	5.04	P/C	0.62	EPS next 5Y	25.50%	ROE	-199.90%	52W Range	1.24 - 17.40	Perf YTD	-68.24%
Dividend	-	P/FCF	-	EPS past 5Y	9.51%	ROI	-101.12%	52W High	-82.07%	Beta	1.92
Dividend %	-	Quick Ratio	0.89	Sales past 5Y	35.52%	Gross Margin	62.29%	52W Low	151.61%	ATR	0.41
Employees	187	Current Ratio	1.00	Sales Q/Q	110.26%	Oper. Margin	-215.16%	RSI (14)	62.17	Volatility	20.24% 17.31%
Optionable	Yes	Debt/Eq	4.44	EPS Q/Q	-273.64%	Profit Margin	-101.67%	Rel Volume	2.99	Prev Close	3.30
Shortable	Yes	LT Debt/Eq	3.88	Earnings	Nov 14 AMC	Payout	-	Avg Volume	462.00K	Price	3.12
Recom	1.67	SMA20	48.50%	SMA50	19.93%	SMA200	-57.49%	Volume	1,383,465	Change	-5.45%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-04-22	Initiated	Ladenburg Thalmann	Buy	$6
Oct-02-20	Initiated	The Benchmark Company	Buy	$9
Dec-18-19	Initiated	B. Riley FBR	Buy	$9
Feb-28-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$11
Mar-22-17	Initiated	JMP Securities	Mkt Outperform
Oct-03-16	Initiated	ROTH Capital	Buy	$9

Dec-06-23 08:30AM	Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics (PR Newswire)
08:30AM	Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd. (GlobeNewswire)
08:00AM	Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea (GlobeNewswire)
Dec-05-23 08:30AM	Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance (GlobeNewswire)
Dec-01-23 08:30AM	Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting (GlobeNewswire) +9.60%
11:18PM	Loading…
Nov-16-23 11:18PM	Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires Shares ... (GuruFocus.com)
Nov-14-23 04:29PM	Fortress Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:10PM	Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Fortress Biotech Announces Closing of $10.0 Million Public Offering (GlobeNewswire)
Nov-13-23 05:00PM	Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-23 08:15AM	Fortress Biotech Announces Pricing of $10.0 Million Public Offering (GlobeNewswire) -37.02%
Nov-09-23 05:05PM	Fortress Biotech Announces Launch of Proposed Public Offering (GlobeNewswire)
Nov-07-23 04:01PM	Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -10.50%
03:00PM	Loading…
Nov-02-23 03:00PM	Avenue Therapeutics Announces Closing of $5.0 Million Public Offering (GlobeNewswire) +15.48%
09:28AM	Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-23 09:15AM	Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) +5.29%
08:30AM	Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-30-23 02:15PM	Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-26-23 12:30PM	Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
09:00AM	Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13R 2 targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma (GlobeNewswire)
Oct-20-23 08:30AM	Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn (Minocycline Hydrochloride Extended-Release Tablets, 105 mg) (GlobeNewswire) -8.37%
Oct-18-23 08:30AM	Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer (GlobeNewswire) -12.69%
Oct-16-23 09:00AM	Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1 (GlobeNewswire)
Oct-09-23 12:50PM	Fortress Biotech Announces Reverse Stock Split (GlobeNewswire) -12.48%
Oct-05-23 08:30AM	Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference (GlobeNewswire)
Oct-02-23 12:53PM	Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds (GlobeNewswire) +7.85%
Sep-21-23 08:30AM	Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire) -5.93%
Sep-07-23 08:30AM	Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
08:15AM	Loading…
08:15AM	Mustang Bio to Participate in Upcoming September 2023 Investor Conferences (GlobeNewswire)
Sep-06-23 08:30AM	Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +9.61%
08:00AM	Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations (GlobeNewswire)
Sep-05-23 08:30AM	Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -10.79%
Aug-16-23 08:00AM	Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy (GlobeNewswire) -9.95%
Aug-14-23 04:19PM	Fortress Biotech: Q2 Earnings Snapshot (AP Finance)
04:15PM	Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:05PM	Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-10-23 04:15PM	Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-08-23 04:01PM	Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-03-23 08:30AM	Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
08:00AM	Mustang Bio to Participate in Two August 2023 Investor Conferences (GlobeNewswire)
Aug-02-23 04:01PM	Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Aug-01-23 02:54PM	Insiders Re-Evaluate Their US$3.4m Stock Purchase As Fortress Biotech Falls To US$77m (Simply Wall St.)
08:30AM	Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study (GlobeNewswire)
Jul-31-23 08:30AM	Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences (GlobeNewswire)
08:00AM	Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market (GlobeNewswire)
Jul-27-23 08:30AM	Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
07:00AM	Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Jul-25-23 08:30AM	Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol (GlobeNewswire) -16.57%
Jul-19-23 08:30AM	Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023 (GlobeNewswire)
Jul-11-23 08:30AM	Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults (GlobeNewswire)
Jul-06-23 08:00AM	Mustang Bio Announces Participation in Upcoming Scientific Meetings (GlobeNewswire) -5.04%
Jul-05-23 02:31PM	Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shift From Loss To Profit (Simply Wall St.)
Jul-03-23 08:00AM	Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023 (GlobeNewswire)
Jun-29-23 08:00AM	Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States (GlobeNewswire) +7.55%
Jun-28-23 08:00AM	Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing (GlobeNewswire) -5.69%
Jun-15-23 04:01PM	Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy (GlobeNewswire) +10.55%
08:00AM	Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program (GlobeNewswire)
Jun-13-23 08:30AM	Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects (GlobeNewswire)
Jun-12-23 08:00AM	Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy (GlobeNewswire)
Jun-08-23 01:18PM	Fortress Biotech, Inc. (NASDAQ:FBIO) Looks Inexpensive But Perhaps Not Attractive Enough (Simply Wall St.)
May-23-23 08:30AM	Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
May-22-23 04:01PM	Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-19-23 04:01PM	Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023 (GlobeNewswire)
May-18-23 08:03AM	Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates (GlobeNewswire) -24.53%
May-15-23 05:15PM	Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:15PM	Fortress Biotech: Q1 Earnings Snapshot (AP Finance)
04:15PM	Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-12-23 04:05PM	Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:30AM	Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-11-23 04:03PM	Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy (GlobeNewswire)
04:01PM	Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call (GlobeNewswire)
May-04-23 10:00AM	Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline (Zacks)
09:00AM	Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023 (GlobeNewswire)
Apr-27-23 08:30AM	Avenue Therapeutics to Present at Aegis Capital Virtual Conference (GlobeNewswire)
Apr-24-23 08:00AM	Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas Short-Form Human Complement Factor H (GlobeNewswire) +9.57%
Apr-18-23 03:35PM	Fortress Biotech (NASDAQ:FBIO) investors are sitting on a loss of 81% if they invested five years ago (Simply Wall St.)
Apr-17-23 04:01PM	Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol (GlobeNewswire)
Apr-03-23 12:15PM	Mustang Bio Announces Reverse Stock Split (GlobeNewswire)
Apr-02-23 08:11AM	Fortress Biotech Full Year 2022 Earnings: Misses Expectations (Simply Wall St.)
Mar-31-23 08:00AM	Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +10.22%
Mar-30-23 08:00PM	Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:10PM	Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-29-23 04:15PM	Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-28-23 08:30AM	Mustang Bio to Participate in Cantors The Future of Oncology Virtual Symposium (GlobeNewswire)
Mar-22-23 09:00AM	Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023 (GlobeNewswire)
Mar-16-23 08:30AM	Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial (GlobeNewswire)
Mar-08-23 04:01PM	Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates (GlobeNewswire) -5.41%
Mar-07-23 08:30AM	Journey Medical Corporation to Participate in the 35th Annual ROTH Conference (GlobeNewswire)
08:00AM	Fortress Biotech to Participate in Two March 2023 Investor Conferences (GlobeNewswire)
Mar-02-23 08:00AM	Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy (GlobeNewswire)
07:00AM	Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma (GlobeNewswire)
Feb-21-23 08:00AM	Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Feb-19-23 07:14AM	The Executive Chairman of Fortress Biotech, Inc. (NASDAQ:FBIO), Lindsay Rosenwald, Just Bought 18% More Shares (Simply Wall St.)
Feb-16-23 08:30AM	Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (GlobeNewswire)

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Nov 14	Buy	1.70	1,567,515	2,664,776	2,597,440	Nov 16 05:50 PM
WEISS MICHAEL S	See Remarks	Nov 14	Buy	1.70	147,058	249,999	1,130,520	Nov 16 05:46 PM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Sep 26	Buy	0.28	100,000	28,330	15,449,091	Sep 27 08:20 AM
Fortress Biotech, Inc.	10% Owner	Sep 08	Buy	0.72	418,410	301,255	1,032,390	Sep 12 09:02 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Aug 18	Buy	9.34	10,000	93,400	112,500	Aug 21 08:30 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Aug 17	Buy	11.75	10,000	117,500	102,500	Aug 21 08:30 AM
ROSENWALD LINDSAY A MD	President, CEO & Chairman	Feb 10	Buy	0.83	2,395,209	2,000,000	15,349,091	Feb 14 04:10 PM
WEISS MICHAEL S	See Remarks	Feb 10	Buy	0.83	1,197,604	999,999	14,752,034	Feb 14 04:12 PM
LOBELL J JAY	Director	Feb 10	Buy	0.83	299,401	250,000	1,635,401	Feb 14 04:07 PM
Jin David	Chief Financial Officer	Feb 10	Buy	0.83	35,928	30,000	1,438,757	Feb 14 04:06 PM
Rowinsky Eric K	Director	Feb 10	Buy	0.83	11,976	10,000	931,976	Feb 14 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FBIO

Fortress Biotech Inc

Upgrade your FINVIZ experience